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The repair of segmental bone defects remains a significant challenge for orthopaedic surgeons. Endothelial progenitor cells (EPCs)
have successfully promoted the repair of acute defects in animal models; however, the ability of EPCs to induce the repair of chronic
nonhealing defects, such as those often encountered clinically, has not been investigated. Therefore, the purpose of this study was to
investigate the ability of EPCs delivered in delayed fashion to induce the repair of nonhealing defects in a clinically relevant model.
In order to simulate delayed treatment, 5mm segmental defects in Fischer 344 rat femora were treated with bone marrow-derived
EPCs on a Gelfoam scaffold at 3 weeks post creation of the defect. At ten weeks posttreatment, 100% of EPC-treated defects
achieved union, whereas complete union was only achieved in 37.5% of defects treated with Gelfoam alone. Furthermore,
significant increases in ultimate torque (p = 0 022) and torsional stiffness (p = 0 003) were found in EPC-treated defects
compared to controls. Critically, no differences in outcomes were observed between acute and delayed EPC treatments. These
results suggest that EPCs can enhance bone healing when applied in an acute or delayed fashion and that their use may
represent a clinically translatable therapy for bone healing in humans.
1. Introduction
Despite recent advances in surgical techniques and
implants, the repair of bone defects and nonunion second-
ary to trauma or infection remains a significant challenge.
Fracture nonunion is a debilitating condition that substan-
tially impacts health-related quality of life and creates a
significant burden on healthcare systems [1–3]. In the tibia
alone, open fractures develop nonunion in 23% of cases
[3] and demonstrate increasing complication rates as frac-
ture severity and bone defect size increase [4–6]. Autologous
iliac crest bone grafting (AICBG) is the current gold standard
of treatment for bone defects; however, bone grafting is
associated with overall complication rates of 19% [7] and
is further limited by the amount of bone available, donor
site morbidity, and suboptimal healing outcomes [7, 8].
Other treatment modalities including vascularized auto-
grafts, cortical allografts, and the Ilizarov technique have
also been utilized for the repair of bone defects [9]. How-
ever, similar to AICBG, each of these techniques have
demonstrated high complication rates and substantial limita-
tions in efficacy. A variety of tissue engineering substitutes,
including osteoinductive molecules such as bone morpho-
genetic proteins (BMPs), osteoconductive scaffolds such
as calcium phosphates, and osteoprogenitor cells such as
mesenchymal stem cells (MSCs), have been investigated
as potentially superior treatments for bone defects [10, 11].
However, to date these therapies have failed to translate into
clinical practice. One potentially significant limitation of
each of these therapies is their lack of angiogenic capacity
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and failure to address blood supply to the tissue-engineering
construct [12].
Accordingly, angiogenic cell populations, such as EPCs,
have recently been investigated, and our research group
[13–16], as well as others [17–19], has successfully demon-
strated the ability of EPCs to affect the repair of segmental
bone defects in animal models when the cells are applied
acutely to freshly created defects. However, the timing of
intervention plays a significant role in the efficacy of both
cellular and molecular therapies [20, 21] as a result of the
differing inflammatory environments at different time
points following trauma. Inflammatory cytokines released
immediately after fracture, such as interleukin (IL)-1 and
IL-6 [22, 23], have been shown to stimulate EPC prolifera-
tion, migration, adhesion, vascular endothelial growth factor
(VEGF) expression, and tubulogenesis [24–26], suggesting
that local inflammation at the fracture site has the potential
to stimulate EPC-mediated repair of acute defects. However,
in the clinical context of open fractures complicated by bone
loss, bone grafting is most commonly delayed to minimize
graft resorption, reduce infection risk, and allow soft tissue
healing at the fracture site [27]. Furthermore, for fractures
that require bone graft treatment for delayed union or non-
union, treatment would typically occur outside of the initial
inflammatory window. Therefore, the environment in which
bone grafting or the application of bone graft substitutes
would typically occur in the clinical situation has not been
well replicated in animal models of EPC therapy, which apply
the cells to acutely created bone defects. The current study
sought to address this by investigating EPC therapy in a more
clinically relevant model of delayed treatment.
The primary objective of this study was to investigate the
use of ex vivo expanded EPCs for the regeneration of bone
defects in a clinically relevant model of delayed treatment
using a chronic bone defect. In addition, we sought to com-
pare delayed delivery of EPCs to EPCs delivered in an acute
fashion to evaluate the effects of treatment timing on func-
tional bone repair. We hypothesized that delayed treatment
with ex vivo expanded EPCs surgically transplanted into
chronic bone defects would enhance bone repair in a compa-
rable fashion to acute treatment.
2. Methods
2.1. Experimental Design. Thirty-six male Fischer 344 synge-
neic rats weighing 250–300 g underwent open surgery to cre-
ate a 5mm segmental defect in the mid-diaphysis of the right
femur, which was then stabilized with a miniplate and
screws. Animals were then randomly assigned to one of five
groups: (1) delayed EPC group: delayed grafting at 3 weeks
post bone defect creation with Gelfoam scaffold (Pfizer,
New York City, NY) loaded with 1× 106 culture-expanded
EPCs in cell culture medium (n = 8); (2) delayed control
group: delayed grafting at 3 weeks post bone defect creation
with Gelfoam control (no cells, soaked in cell culture medium
only) (n = 8); (3) empty defect control group: no additional
treatment at 3 weeks post bone defect creation (n = 8); (4)
acute EPC group: immediate grafting of bone defect with
Gelfoam scaffold loaded with 1× 106 culture-expanded EPCs
in cell culture medium (n = 6); or (5) acute control group:
immediate grafting with Gelfoam control (no cells, soaked
in cell culture medium only) (n = 6). Animals receiving
immediate treatment were sacrificed after 10 weeks. In the
delayed treatment and empty defect control groups, defects
were left empty for the initial 3-week delay, and animals were
sacrificed 10 weeks thereafter. All animals were sacrificed
by intracardiac injection of T-61 solution while under 2%
isofluorane anaesthetic. In all groups, the operated and non-
operated femora were dissected immediately postsacrifice
and then fixed in 10% neutral buffered formalin. All proto-
cols were approved by the St. Michael’s Hospital Animal
Care Committee.
2.2. Cell Isolation, Culture, and Characterization. The cell
isolation protocol used in this study was modified from
our previous protocol [16] and has been published else-
where [28]. Briefly, bone marrow was flushed from the
medullary canals of rat tibiae and femora with phosphate
buffered saline (PBS). Washout solution was collected
and subsequently centrifuged at 360g for 10 minutes at
18°C. The resulting cell pellet was resuspended in endothelial
basal medium (EBM-2) supplemented with EGM-2 MV
SingleQuots™ (Lonza, Walkersville, MD). The cell solution
was transferred to a T-75 flask previously coated with fibro-
nectin (10mg/mL). Nonadherent cells were removed after
48 h, and the culture was continued for 7-8 days with
medium changes every other day.
Cultured cells were characterized according to their
ability to uptake Ac-LDL and bind UEA-1 lectin. Cells loaded
onto glass coverslips were incubated with 10μg/mL of Alexa
Fluor® 594 Ac-LDL (Molecular Probes, Eugene, OR) for
4 h at 37°C and 5% CO2. Cells were then fixed with 2%
paraformaldehyde for 10 minutes, incubated with 20μg/mL
of FITC UEA-1 lectin (Sigma-Aldrich, St. Louis, MO) over-
night at 4°C, and subsequently visualized on a fluorescence
microscope (Nikon Eclipse E800, Tokyo, Japan). Addition-
ally, a tube formation assay was used to assess the angiogenic
potential of the cultured cells. Basement membrane Matrigel
(BD Biosciences, Franklin Lakes, NJ) diluted 1 : 2 in EBM-
2 medium was loaded into a 12-well plate at 300μL/well
and was allowed to polymerize at 37°C and 5% CO2 for
15 minutes. EPCs were added onto the Matrigel at
25,000 cells/cm2 and were incubated for 24 h at 37°C and
5% CO2. After 24 h, the medium was carefully aspirated,
and Calcein AM diluted in EGM-2 MV medium was
added to each well at 2μg/mL. Plates were then imaged
at 10× objective using fluorescence microscopy (Zeiss Axio
Observer Live Cell, Oberkochen, Germany). Ten z-stacks
at 10μm intervals were acquired with ApoTome and shading
correction. Sixteen images in a 4× 4 layout were captured,
and individual stacks and tiles were stitched together to cre-
ate a composite 3D image using Imaris software (Bitplane,
Belfast, UK).
2.3. Surgical Procedures. The femoral bone defect surgery has
been previously described in an earlier study [16]. Briefly,
rats were anaesthetized with 2% isofluorane and given
0.05mg/kg of buprenorphine analgesic preoperatively via
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subcutaneous injection. The right leg was shaved and then
scrubbed with Betadine solution (povidone-iodine, 10%)
and 70% ethanol. All further steps took place under sterile
conditions. Using a lateral approach, an incision was made
in the skin overlying the femur, and the underlying tissue
was dissected to expose the bone surface. Two parallel
osteotomies were created in the middle 1/3 of the femoral
diaphysis using an oscillating saw with 0.9% saline irrigation.
The intervening bone segment was removed, and a 5-hole
mini-plate (Synthes, Mississauga, Canada) was fixed to the
bone with two proximal and two distal 1.5mm cortical
screws. In the delayed treatment groups, the defect was left
empty and a standardized closure was performed. In the
acute treatment groups, either EPC-loaded Gelfoam or
Gelfoam control was placed in the defect prior to closure.
Rats were allowed full weightbearing and cage activity post-
operatively and were given 0.05mg/kg of buprenorphine
analgesic every 12 hours for the first 48 hours postsurgery.
During the secondary surgery for the delayed treatment
groups, anaesthetic and analgesics were given as described
above, and the same surgical approach was utilized to access
the femur. Subsequently, the defect was cleared of fibrous tis-
sue, and the bone ends were debrided with a scalpel to induce
cortical bleeding. A 20-gauge needle was then used to rees-
tablish the medullary canal, which had typically been covered
over by endosteal callus and fibrotic tissue. Then, either EPC-
loaded Gelfoam or Gelfoam control was placed in the defect
prior to closure.
2.4. Radiographic Assessment. All animals assigned to receive
delayed treatment or no treatment underwent plain radio-
graphic evaluation after the initial 3-week delay. Defects were
scored in a blinded fashion using a radiographic scoring sys-
tem modified from Atesok et al. [16] (Table 1), and defects
with scores of 4 or lower were randomized to receive either
EPC-loaded Gelfoam or Gelfoam control or to be left empty
with no further surgical intervention. Defects receiving
scores of 5 or greater were excluded from further study in
order to ensure that the repair of the defect was a result of
the intervention and not spontaneous bone repair.
Postintervention, standardized radiographs were taken
on a biweekly basis to monitor bone repair. Radiographs
taken at the 10-week endpoint were graded using the scoring
system outlined in Table 1. Two blinded orthopaedic sur-
geons graded all radiographs, and the average scores were
used for analysis. Additionally, defects were characterized
as completely united, incompletely united, or nonunited by
a blinded orthopaedic surgeon.
2.5. MicroCT Analysis. After specimen harvest and plate
removal, the operated femora were placed vertically in a
poly-ethyl-imid (PEI) holder (16.4mm×75mm) filled with
formalin solution. The samples were scanned at 70 kVp
and 114μA in high resolution (1000 projections per 180°;
voxel size = 8 μm) on a MicroCT40 system (Scanco Medi-
cal, Basserdorf, Switzerland). The integration time of each
projection was 300ms, and a single scan at each projection
was conducted (frame averaging = 1). Prior to analysis, the
2D transverse (x-z) grayscale images (1206–1344 total
sections) were reconstructed to x-y cross sections (voxel
size = 8 μm; image size = 2048 × 2048 pixels). A rectangular
region of interest (ROI) encapsulating the osteotomy site at
its widest point was drawn on x-y sections, using the margins
of native bone as reference points. For each specimen, the
same ROI was applied across all slices with visible cortex,
creating a 3D rectangular volume of interest (VOI) (mean
volume± standard error (SE): 72.26± 1.430mm3). Threshold
for morphometric analysis was held constant across all slices
and samples (minimum = 263; maximum = 1000), and the
VOIs were analyzed for quantitative bone morphometry.
Analysis included the following morphometric parameters:
bone volume to total volume fraction (BV/TV (1)), trabecu-
lar number (Tb.N∗ (1/mm)), trabecular separation (Tb.Sp∗
(mm)), and trabecular thickness (Tb.Th∗ (mm)).
2.6. Biomechanical Analysis. After microCT analysis, the
femora were taken for biomechanical testing on an MTS
Bionix 858 test system (MTS Systems, Eden Prairie, MN). A
12 in-lb torsional load cell (Futek TFF325, Irvine, CA) was
utilized to ensure optimal testing accuracy. To prepare each
sample, the proximal and distal epiphyseal-metaphyseal
segments of the bones were first potted in polymethyl
methacrylate (PMMA) dental cement. The diaphyseal defects
were centred between two potting casings using a 20mm
gauge length, and the femoral diaphyses were aligned longi-
tudinally to the axis of the machine. The femora were tested
in torsion at a displacement of 1°/second until failure of the
bone or a total displacement of 40°. Ultimate torque and
torsional stiffness were used for analysis.
2.7. Statistical Analysis. All statistical analyses were per-
formed on GraphPad Prism version 6.0 (GraphPad Software,
Inc., La Jolla, CA). Analyzed values are expressed as mean -
± SE. Data were evaluated using two-way analysis of vari-
ance (ANOVA), with Tukey’s honest significant difference
(HSD) multiple comparisons analysis to identify between-
group differences. A p value of <0.05 was considered statisti-
cally significant.
3. Results
3.1. Isolation and Characterization of EPCs. The isolated cell
population displayed spindle-shaped morphology character-
istic of EPCs after 7-8 days in culture (Figure 1(a)). Harvested
Table 1: Radiographic scoring system.















cells were capable of forming tube-like structures when
seeded on Matrigel (Figure 1(b)), and stained double positive
for Ac-LDL uptake and UEA-1 lectin binding (Figure 1(c)).
3.2. Bone Defect Model. At 3 weeks post bone defect creation,
nine animals were excluded from further study as a result of
radiographic scores greater than 4 (mean score: 5.11± 0.11).
Twenty-four animals had scores of 4 or lower, and were thus
included for randomization and further study. Prior to repeat
intervention, the mean radiographic score of animals in the
delayed EPC group (2.00± 0.33) was not significantly differ-
ent from those in the delayed control group (1.75± 0.35) or
the empty defect control group (1.50± 0.42). Histological
staining of empty defects 3 weeks post bone defect creation
revealed disorganized fibrous tissue and prolapsed muscle
tissue filling the bone defect and endosteal callus capping
the proximal and distal fracture fragments (data not shown).
The mean endpoint radiographic score for the empty
defect control group was 2.5± 0.62, and six of eight (75.0%)
defects went on to radiographic nonunion. The remaining
two defects were considered incompletely united; however,
only one had bridging bone upon microCT and biome-
chanical analyses.
3.3. Treatment with EPCs Improves Radiographic Healing.
Radiographs of animals from the treatment and control
groups were analyzed. By two-way ANOVA analysis, animals
treated with EPCs had significantly greater radiographic
scores at 10 weeks compared to controls (6.89 ±0.15 versus
4.29± 0.67; p < 0 001), whereas no difference existed between
animals treated in an acute versus delayed fashion. Addi-
tionally, all animals receiving EPCs achieved complete
union within 10 weeks of treatment irrespective of the
timing of cell delivery, whereas control animals demon-
strated significantly lower overall union rates.
In our multiple comparisons analysis, radiographic
scores were not significantly different between the
delayed EPC and delayed control groups (6.94± 0.11 versus
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100 휇m
(c)
Figure 1: Culture and characterization of rat bone marrow-derived EPCs. (a) Cultured cells displayed spindle-shaped morphology
characteristic of EPCs after 7–8 days in culture. (b) EPCs formed tube-like structures after seeding on Matrigel for 24 hours (stained with
Calcein AM). (c) EPCs were characterized by Ac-LDL uptake and UEA-1 lectin binding.
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5.25± 0.79; p = 0 212) (Figure 2(a)). However, all eight
(100%) animals in the delayed EPC group achieved complete
union, whereas complete union only occurred in three of
eight (37.5%) animals in the delayed control group
(Table 2). Similarly, all six (100%) animals in the acute EPC
group achieved complete union, whereas complete union
was not observed in any of the animals in the acute control
group. Furthermore, the acute EPC group had significantly
higher radiographic scores than the acute control group
(6.83± 0.33 versus 3.00± 0.97; p = 0 003). Radiographic
scores were not significantly different between delayed and
acute application of EPCs, nor between delayed and acute
treatment with Gelfoam control. Representative radiographs
from each group are shown in Figure 2(b).
3.4. Treatment with EPCs Enhances Bone Morphometric
Parameters.Quantitative microCT performed 10 weeks post-
intervention revealed significant differences in bone mor-
phometry between EPC-treated and control groups. By
two-way ANOVA analysis, treatment with EPCs significantly
increased bone volume fraction (p < 0 001) and trabecular
number (p < 0 001), and decreased trabecular separation
(p < 0 001) compared to controls (Figure 3). Trabecular
thickness was unchanged between EPC-treated and control
groups. No differences were observed between animals
treated acutely versus in a delayed fashion.
In our multiple comparisons analysis, bone volume
fraction was unchanged in the delayed EPC group compared
to the delayed control group (p = 0 115) (Figure 4(a)). How-
ever, compared to the delayed control group, animals treated
in a delayed fashion with EPCs demonstrated significantly
greater trabecular number (p = 0 005) and significantly
reduced trabecular separation (p = 0 007). When applied
in an acute fashion, EPCs significantly increased bone
volume fraction (p = 0 003), increased trabecular number
(p = 0 010), and decreased trabecular separation (p = 0 005)
compared to control. Trabecular thickness was unchanged
in all groups. Bone morphometric parameters did not differ
between delayed and acute application of EPCs. Figure 4(b)
demonstrates representative 3D reconstructions and x-y
cross sections of bone defects from each group.
3.5. Treatment with EPCs Increases Biomechanical Strength
and Stiffness. Biomechanical testing at 10 weeks postinter-
vention revealed significant improvements in EPC-treated
versus control animals. By two-way ANOVA analysis, treat-
ment with EPCs significantly increased ultimate torque
(149.53± 12.51 versus 45.65± 20.44; p < 0 001) and torsional
stiffness (30.55± 1.81 versus 8.34± 3.61; p < 0 001) compared
to controls.
In our multiple comparisons analysis, delayed applica-
tion of EPCs to bone defects significantly improved ulti-
mate torque (166.23± 14.05 versus 72.14± 32.67; p = 0 022)
and torsional stiffness (33.01± 2.74 versus 14.17± 5.56;
p = 0 003) compared to control (Figure 5). Importantly, the
Table 2: Radiographic union rates.
Acute Delayed



















































Figure 2: Treatment of bone defects with EPCs improves radiographic healing. (a) Radiographic scores of rat femoral defects at 10 weeks. The
difference between EPC treatment and control was statistically significant when treatment was applied acutely but not when treatment was
performed in a delayed fashion. No difference was observed between delayed EPC and acute EPC groups. (b) Representative radiographs
of defects in each group. Complete radiographic union was observed in all animals receiving EPCs, whereas control groups generally
demonstrated incomplete union or nonunion. ∗ denotes significant difference between groups (p < 0 05).
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delayed EPC group demonstrated consistent regeneration of
functional strength and stiffness, whereas only four of eight
(50%) animals in the delayed control group had mechanical
stability across the defect. Acute delivery of EPCs resulted
in significantly improved ultimate torque (127.26± 20.20
versus 10.32± 10.32; p = 0 012) and stiffness (27.27± 1.44
versus 0.56± 0.56; p < 0 001) compared to acute delivery of
Gelfoam-only control. No differences in ultimate torque or
torsional stiffness were observed between delayed and acute
treatment with EPCs, nor between delayed and acute treat-
ment with Gelfoam control.
4. Discussion
The reconstruction of bone defects resulting from trauma or
nonunion remains a considerable challenge for orthopaedic
surgeons. While acute treatment with EPCs has proven effec-
tive in small animal models, patients presenting with trau-
matic fractures neither have a readily available source of
EPCs nor have a biological environment at the fracture site
conducive to acute bone reconstruction. In the clinical set-
ting, EPCs would likely be applied during a later secondary
surgery, creating a discrepancy between current models and
potential clinical use. The present study aimed to address this
discrepancy, and our findings indicate that EPCs delivered
via open surgery to a previously established bone defect are
indeed capable of inducing bone repair. Although the volume
of bone formed upon delayed delivery of EPCs did not differ
significantly from the control group, the rate of union and
quality of the bone were far superior when defects were
treated with EPCs. Furthermore, at 10 weeks posttreatment,
defects treated in a delayed fashion with EPCs recovered to
approximately 65% of nonoperated contralateral bone
strength. The mechanical superiority of defects treated
with EPCs may in part be attributed to the more abundant
and more tightly spaced trabeculae in the EPC group;
however, EPCs appeared to contribute significantly by
enhancing the rate and quality of defect union. Thus,
EPCs administered to nonhealing bone defects evidently
enhanced bone healing when compared to control treat-
ment, and therefore, EPCs could be a clinically translatable
therapy aimed at the reconstruction of osseous defects in a
delayed fashion.
As part of our objective, we aimed to evaluate the influence
of timing of EPC application on defect repair. Comparison
between acute and delayed EPC treatment demonstrated no
significant differences in bone repair between the groups, sug-
gesting that treatment with EPCs at either an acute or delayed
stage is effective for the repair of bone defects. These findings
are inconsistent with previous investigations of delayed defect
reconstruction using cellular and molecular therapies, as
delayed treatmenthas beenunable to inducehealing responses
equivalent to those observed with acute treatment [20, 21].
These differences may be explained by our secondary surgical
procedure in which we elevated the soft tissue envelope and
reestablished the medullary canal in a comparable fashion to
that used clinically in exchange nailing procedures. While
exchange nailing stimulates bone union by replacing a smaller
unreamed nail with a larger reamed nail to enhance the stabil-
ity at the fracture site, reaming the medullary canal for place-
ment of the nail stimulates periosteal circulation and likely
promotes novel angiogenic stimuli capable of enhancing bone
repair [29]. Similarly, in the model used in the current study,
elevationof the soft-tissue envelope andopeningof themedul-
lary canal may promote sufficient circulation and angiogenic
stimuli to induce a healing response in combination with
EPCs. Thus, the ability of EPCs to induce adequate bone repair
when treated either immediately after fracture or at a delayed
time point demonstrates the potential clinical utility of EPCs
in bone defect reconstruction.
The mechanisms of EPC-induced bone repair remain
incompletely understood. However, it is well established
that a complex, coordinated coupling of angiogenesis and
osteogenesis is essential to bone regeneration. In normal
healing fractures, BMP-2 and BMP-7 are upregulated at 1
and 14–21 days postfracture, namely, the acute inflammatory
stage and the stage of endochondral ossification [23]. Con-
versely, these BMPs are downregulated in models of atrophic
nonunion compared to standard healing controls [30, 31].
Increased VEGF expression after EPC application may
help to stimulate BMP-2 expression in local endothelial cells
[13, 14, 32]. Synergistically, BMP-2 also stimulates VEGF
expression in osteoblasts, further suggesting the coupling
of angiogenesis and osteogenesis [33]. Thus, EPC-induced
expression of VEGF and BMP-2 [13, 14], even after signifi-
cant delay, may help to overcome the deficient signalling
present in fracture nonunion and may initiate the inflam-
matory and endochondral phases of bone repair through





















































Figure 3: Treatment with EPCs increases bone formation and
improves bone morphometric parameters. Global comparison
between EPCs and Gelfoam-only controls revealed increased bone
volume fraction, increased trabecular number, and decreased
trabecular separation when treated with EPCs. Trabecular thickness
was unchanged between groups. ∗ denotes significant difference
between groups (p < 0 05).
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the secondary surgical procedure is likely to cause an inflam-
matory reaction, which may stimulate EPC activity via IL-1
and IL-6 signalling [24–26]. Still, further investigation into
the molecular pathways involved in EPC-mediated bone
repair is required, and identification of these mechanisms
and their interaction with inflammatory processes may aid
in tailoring EPC treatments for clinical use.
The limitations of this study include the investigation of a
single delayed time point, and the spontaneous union
observed in a small subset of animals. First, the 3-week delay
used in this study was chosen based on the accelerated biol-
ogy observed in rodent fracture repair in comparison to
humans [34]. Bone grafting immediately after open fracture





























































Figure 4: Treatment of bone defects with EPCs enhances bone morphometric parameters. (a) Graphical representation of quantitative
microCT parameters. When applied in a delayed fashion, EPCs increased trabecular number and decreased trabecular separation
compared to control. When applied acutely, EPCs increased bone volume fraction and trabecular number, and decreased trabecular
separation. No differences in any parameter were observed between acute and delayed delivery of EPCs. (b) 3D reconstructions and x-y
cross sections of representative defects from each group (BV/TV nearest the group mean). Treatment with EPCs, either in an acute or
delayed fashion, demonstrated complete defect bridging at 10 weeks postintervention, whereas incomplete union or nonunion was
generally observed in the control groups. ∗ denotes significant difference between groups (p < 0 05).
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resorption resulting from the inflammatory reaction [27, 35].
Instead, delayed bone grafting is normally performed once
the soft tissue envelope has adequately healed and inflamma-
tion has subsided, often between 6 and 8 weeks postinjury
[35]. In comparison to high-energy open fractures in human
long bones, the rat model utilized in this study achieves soft
tissue closure relatively early after the operation because min-
imal iatrogenic damage occurs during the fracture surgery.
Three weeks postfracture, inflammation has significantly
decreased [22, 23], re-epithelialization has occurred, and
based on histological evidence not included in this study,
the defect has been filled with fibrous tissue. All of these fac-
tors considered, we concluded that a 3-week delay in our rat
model sufficiently replicated the clinical scenario. Still, fur-
ther investigation with later time points would strengthen
the applicability of this study. Second, it could be argued that
the regeneration of bone was a result of spontaneous union
and not the administration of EPCs. However, animals were
only subjected to randomization if their radiographic score at
3 weeks was 4 or lower, so as to include only animals with
nonhealing defects. Additionally, we confirmed the nonheal-
ing nature of the bone defects in the study by including a
group of animals in which the defect was left empty with
no secondary intervention. The failure of defect bridging in
this group provides sufficient evidence to conclude that
bony regeneration in the treatment groups was indeed a
result of secondary surgical intervention and not natural
bone repair.
5. Conclusion
Our results indicate that EPCs are capable of enhancing
radiographic and morphometric bone repair when applied
3 weeks after bony injury, and promote greater and more
consistent recovery of biomechanical function compared
to a control group. Importantly, the healing response
observed upon delayed surgical treatment did not differ
from that of acute treatment. These data suggest that open
surgical delivery of EPCs on a collagen carrier may be
effective when used in a delayed fashion for the treatment
of nonhealing bone defects in a clinically relevant scenario.
Based on the results from this study, EPC-based therapy
could represent a substantial advance for the treatment
of nonunions and traumatic bone defects in humans, and
further research aimed at bringing this novel therapy to
the clinical realm is warranted.
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